The latest news

Studies, publications & press releases

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Posters & Abstracts

Oct 27, 2026

ESMO 26: AI Digital Pathology Models Estimate Chemotherapy Benefit and Risk of Distant Recurrence in Patients From the NSABP B-20 Study

See More

Oct 27, 2026

ESMO 26: AI Digital Pathology Models Estimate Chemotherapy Benefit and Risk of Distant Recurrence in Patients From the NSABP B-20 Study

See More

Press Releases

Dec 4, 2025

PreciseDx Presents New Data for PreciseBreast, an AI Digital Pathology Test to Predict Breast Cancer Recurrence, at the 2025 San Antonio Breast Cancer Symposium

See More

Dec 4, 2025

PreciseDx Presents New Data for PreciseBreast, an AI Digital Pathology Test to Predict Breast Cancer Recurrence, at the 2025 San Antonio Breast Cancer Symposium

See More

Publications

Aug 20, 2025

External validation of PreciseBreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands

See More

Aug 20, 2025

External validation of PreciseBreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands

See More

Press Releases

Jun 18, 2025

PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership

See More

Jun 18, 2025

PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership

See More

Posters & Abstracts

Dec 9, 2024

San Antonio Breast Symposium-24: PreciseBreast, an AI-digital pathology test to predict breast cancer recurrence

See More

Dec 9, 2024

San Antonio Breast Symposium-24: PreciseBreast, an AI-digital pathology test to predict breast cancer recurrence

See More

Press Releases

Nov 20, 2024

PreciseDx Announces Formation of Scientific Advisory Board

See More

Nov 20, 2024

PreciseDx Announces Formation of Scientific Advisory Board

See More

Press Releases

Aug 21, 2024

PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments

See More

Aug 21, 2024

PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments

See More

Media Coverage

Aug 2, 2024

As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation

See More

Aug 2, 2024

As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation

See More

Press Releases

Jul 23, 2024

PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™ (PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics

See More

Jul 23, 2024

PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™ (PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics

See More

Publications

Jul 9, 2024

U.S. Payer Budget Impact of Using an AI-Augmented Cancer Risk Discrimination Digital Histopathology Platform to Identify High-Risk of Recurrence in Women with Early-Stage Invasive Breast Cancer

See More

Jul 9, 2024

U.S. Payer Budget Impact of Using an AI-Augmented Cancer Risk Discrimination Digital Histopathology Platform to Identify High-Risk of Recurrence in Women with Early-Stage Invasive Breast Cancer

See More

No results.

Let us show you the significance of PreciseBreast®

Contact us today to learn more.

Get in Touch